The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute ...
The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute myocardial infarction (AMI) and unstable angina, an aging global population ...
Welcome to the Novartis presentation at the 43rd JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan. It's my great pleasure to introduce Vas Narasimhan, the CEO ...
The company already had heart failure data on valsartan, which has been marketed for hypertension as Diovan for years, but he noted that "heart failure is not like blood pressure. I don't know ...